Stock Research: Bioventus

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Bioventus

NasdaqGS:BVS US09075A1088
40
  • Value
    14
  • Growth
    63
  • Safety
    Safety
    83
  • Combined
    57
  • Sentiment
    27
  • 360° View
    360° View
    40
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 40 (better than 40% compared with alternatives), overall professional sentiment and financial characteristics for the stock Bioventus are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Bioventus. The consolidated Value Rank has an attractive rank of 83, which means that the share price of Bioventus is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 83% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 63, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 27. Professional investors are more confident in 73% other stocks. Worryingly, the company has risky financing, with a Safety rank of 14. This means 86% of comparable companies have a safer financing structure than Bioventus. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
83 63 88 81
Growth
63 97 21 99
Safety
Safety
14 1 10 36
Sentiment
27 18 26 24
360° View
360° View
40 38 15 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
71 28 15 50
Opinions Change
50 50 89 50
Pro Holdings
n/a 54 28 30
Market Pulse
8 5 5 30
Sentiment
27 18 26 24
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
83 63 88 81
Growth
63 97 21 99
Safety Safety
14 1 10 36
Combined
57 66 27 96
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
96 73 87 96
Price vs. Earnings (P/E)
83 65 83 79
Price vs. Book (P/B)
58 55 71 43
Dividend Yield
1 1 1 1
Value
83 63 88 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
34 6 10 71
Profit Growth
86 100 12 94
Capital Growth
86 100 36 99
Stock Returns
17 99 97 39
Growth
63 97 21 99
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
8 16 18 14
Refinancing
45 32 53 31
Liquidity
50 54 25 81
Safety Safety
14 1 10 36

Similar Stocks

Discover high‑ranked alternatives to Bioventus and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Cigna

NYSE:CI
Country: USA
Industry: Health Care Services
Size: XX-Large
Full Stock Analysis

TEGNA

NYSE:TGNA
Country: USA
Industry: Broadcasting
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.